openPR Logo
Press release

Pharmacogenomic (PGx) Testing Market Exhibits Higher Growth Prospects during 2018-2028 // Bayer AG, Abbott Laboratories, Inc., Thermo Fisher Scientific Inc., AstraZeneca PLC, QIAGEN

05-07-2019 11:31 AM CET | Industry, Real Estate & Construction

Press release from: Fact.MR

Pharmacogenomic (PGx) Testing Market Exhibits Higher Growth

Increasing use of the patient specific treatment expected to drive the growth of the pharmacogenomic (PGx) testing market. The increasing emphasis of healthcare professionals to minimize sever adverse reactions of medication which varies person to person tremendously further expected to drive the growth of the Pharmacogenomic (PGx) Testing Market. The growing patient specific approach for the treatment of chronic diseases and study of factors which can impact treatment such as genetic factors which may influence the desired action of medication further expected to fuel the growth of pharmacogenomic (PGx) testing market.

Request TOC of this Report- https://www.factmr.com/connectus/sample?flag=T&rep_id=3143

The genetic make-up is unique for each person and it doesn’t change hence pharmacogenomic (PGx) testing helps in choosing the patient specific treatment option driving the growth of the market. Pharmacogenomic (PGx) testing enables physicians to choose better suited treatment for the particular patient in turn helping to attain better therapeutic effect driving the growth of the pharmacogenomic (PGx) testing market. Whereas, low awareness among the general population and healthcare professionals may hamper the potential growth of the market.

Pharmacogenomic (PGx) testing is study of the effect of individual genetic make-up on the therapeutic effect of the medication. The individual response to the medication is determined by the various factor such as weight, age, diet, habits, and genetic factors, etc. The genetic make-up of the individual majorly decides the metabolism rate of the medication along with other factors. Depending on the variation in person to person gene make-up, metabolism of the medication varies significantly. One drug that works efficiently may not work for the other person due to variation in the time for metabolism. For example, prodrugs administered are required to be converted into the active form for the therapeutic effect whereas if the metabolism rate is too slow then amount of the prodrug converted to active form may be very less hampering the desired bioavailability of actual active drug which in turn may not work. Whereas, if the metabolism is too fast for the prodrug then too much of active drug can result in the hyperactivity.

To know more about the Pharmacogenomic (PGx) Testing Market Visit the link- https://www.factmr.com/report/3143/pharmacogenomic-pgx-testing-market

Pharmacogenomic (PGx) Testing Market: Overview

The increasing episodes of the adverse reactions in patients forcing healthcare professionals as well as manufacturers to alter the traditional treatment method, which is one of the major factor driving the growth of pharmacogenomic (PGx) testing market. By test type, diagnostic tests expected to dominate the global market. Whereas, by application pharmacogenomic (PGx) testing market is expected to be dominated by the oncology segment due to higher reports of life threatening adverse reactions in the cancer patients. By end user the global pharmacogenomic (PGx) testing market is expected to be dominated by the diagnostic laboratories due to higher patient footfall for the test. The manufacturers in the global pharmacogenomic (PGx) testing market are focusing on the research and development activity.

Pharmacogenomic (PGx) Testing Market: Regional Outlook

The global pharmacogenomic (PGx) testing market is dominated by the North America due to availability of high end products for the pharmacogenomic (PGx) testing. Europe is expected to be second most lucrative pharmacogenomic (PGx) testing market in due to higher reports of adverse reactions and for the prevention more physicians are preferring use of pharmacogenomic (PGx) testing. Asia-Pacific is the emerging market due to increasing awareness about the availability of such pharmacogenomic (PGx) testing to minimize adverse events. Latin America pharmacogenomic (PGx) testing market is expected to experience gradual growth whereas Middle East and Africa is expected to be least lucrative pharmacogenomic (PGx) testing market due to low product penetration in the most part of the region.

Pharmacogenomic (PGx) Testing Market: Key Players

The key market players operating in the pharmacogenomic (PGx) testing market are: Affymetrix, Inc., Becton Dickinson and Company, Bayer AG, Abbott Laboratories, Inc., Thermo Fisher Scientific Inc., AstraZeneca PLC, QIAGEN and others. 

The research report presents a comprehensive assessment of the Pharmacogenomic (PGx) Testing market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to Pharmacogenomic (PGx) Testing market segments such as geographies, application, and industry.

Request Brochure of this Report- https://www.factmr.com/connectus/sample?flag=B&rep_id=3143

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Read Industry News at - https://www.industrynewsanalysis.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pharmacogenomic (PGx) Testing Market Exhibits Higher Growth Prospects during 2018-2028 // Bayer AG, Abbott Laboratories, Inc., Thermo Fisher Scientific Inc., AstraZeneca PLC, QIAGEN here

News-ID: 1729593 • Views: 4550

More Releases from Fact.MR

Hand Sanitizer Market to Surpass US$ 2.8 Bn, Instant Hand Sanitizer Poised to Ho …
The global hand sanitizer market is set to surpass a value of ~US$ 1.4 Bn in 2020 and is anticipated to cross US$ ~2.8 Bn during the forecast period 2020-2030. The demand for gel-based sanitizer is on the rise as compared to foaming or spray sanitizer. Thus, manufacturers are focusing on developing gel-based sanitizers as they are widely used in multiple end-use industries. With the increased penetration of the online
03-20-2020 | Health & Medicine
Fact.MR
Medical Marker Bands Market Grows on the back of Their Radiopacity and Cost-effe …
Radiopacity of medical marker bands is giving significant impetus to their demand in the medical marker bands market. The properties of medical marker bands that increases their visibility under fluoroscopes or x-ray during critical procedures is giving an uptick to their sales worldwide. Manufacturers of medical marker bands are also showing a marked preference for cost-effective materials such as polymer and tantalum instead of traditional gold, platinum and palladium. On
Plastic Tray Market Showcases Future Status of Prime Manufacturers Across Major …
The new report on the global plastic tray market gives estimations of the size of the international market and the overall size and share of key regional segments during the historical assessment period of 2013 - 2017. The overall outlook for the Plastic Tray Market is likely to remain sluggish, with the plastic tray market expected to reach CAGR of 3.6% in terms of revenue during 2018-2027. The business knowledge
MRI-guided Radiation Therapy Systems Market Leading Manufacturers Expected to Mo …
With a multi-disciplinary approach, Fact.MR elaborates an extensive analysis of the historical, current and future outlook of the global MRI-guided radiation therapy systems market as well as the factors responsible for such a growth. Our highly dedicated professionals have provided critical and accurate insights associated with every industry, and region by doing thorough primary and secondary research. Access Research Methodology Prepared By Experts - https://www.factmr.com/connectus/sample?flag=RM&rep_id=2572 We leverage space-age industrial and digitalization tools

All 5 Releases


More Releases for PGx

Pharmacogenomic (PGx) Testing Market Size Projected to Rise Lucratively during 2 …
Pharmacogenomic (PGx) testing is study of the effect of individual genetic make-up on the therapeutic effect of the medication. The individual response to the medication is determined by the various factor such as weight, age, diet, habits, and genetic factors, etc. The genetic make-up of the individual majorly decides the metabolism rate of the medication along with other factors. Depending on the variation in person to person gene make-up, metabolism
Pharmacogenomics Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Pharmacogenomics Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 124 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. Click to view the full report TOC, figure and tables: https://www.globalinforesearch.com/global-paediatric-sports-medicine-market_p104058.html   Pharmacogenomics is the study of the role of the
Global Pharmacogenomics (PGx) Market 2019 Key Players: Abbott Laboratories, Affy …
Pharmacogenomics (PGx) Market: WiseGuyReports.com adds “Pharmacogenomics (PGx) Market 2019 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting 2025” reports to its database. Executive Summary Pharmacogenomics is the study of the role of the genome in drug response. Its name reflects its combining of pharmacology and genomics. Pharmacogenomics analyzes how the genetic makeup of an individual affects his/her response to drugs. In 2018, the global Pharmacogenomics (PGx) market size was xx million US$ and
Pharmacogenomics Market size and Key Trends in terms of volume and value 2017-20 …
Global Pharmacogenomics Market Information by Application (Tailor treatments, drug discovery), By Therapeutic application, By Methods - Forecast to 2027 Market Research Future adds new report of “Global Pharmacogenomics Market Research Report - Forecast to 2027” it contains Company information, geographical data and Table of Content Competitive Analysis: RPRD (Right Patient Right Drug) Diagnostics, a privately-held, Wisconsin-based precision medicine company, on February 2017, declared a strategic partnership with Orient Bio Inc., a leading South
Genetic Disease Diagnostic Market : Industry Insights With Key Company Profiles …
Genetic mutations are change in the deoxyribonucleic acid (DNA) sequence of an individual. Genes are responsible for formation of proteins that perform majority of functions of the body. Thus abnormality in genes results in faulty or no protein formation leading to abnormal functioning of the body. One or multiple abnormalities in genome resulting from mutations or changes in DNA sequence causing illness are referred as genetic disease. Genetic disease
Genetic Disease Diagnostic Market: Emerging Trends & Upcoming Pharmaceutical Res …
Genetic mutations are change in the deoxyribonucleic acid (DNA) sequence of an individual. Genes are responsible for formation of proteins that perform majority of functions of the body. Thus abnormality in genes results in faulty or no protein formation leading to abnormal functioning of the body. One or multiple abnormalities in genome resulting from mutations or changes in DNA sequence causing illness are referred as genetic disease. Genetic disease